Internet Archive Scholar

Ombitasvir/ Paritaprevir/ Ritonavir + Ribavirin Combination Therapy in Hepatitis C Virus Infected Patients with Genotype 4 in Real-life Practice: A Multicentre Experience

Bilgehan Aygen, Nese Demirturk, Orhan Yıldız, Ilhami Celik, Deniz Kamalak Guzel, Gulden Ersoz, Ayse Batirel, Bahar Ormen, Faruk Karakecili, Pinar Korkmaz, Nazan Tuna, Alper Sener (+7 others)
2019 Infectious Diseases and Clinical Microbiology  

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (197.6 kB)
https://web.archive.org/web/20200307024709/https://www.idcmjournal.org/wp-content/uploads/2019/09/IDCM_2019_0014.pdf

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL. The file type is application/pdf.

Objective: Objective: Ombitasvir/paritaprevir/ritonavir (OMV/PTV/r) + ribavirin (RBV) combination improved the efficacy, safety, and tolerability of the treatment of chronic hepatitis C virus (HCV) genotype 4 infection. We described the effectiveness and safety of OMV/PTV/r + RBV therapy in patients with genotype 4 infection. Materials and Methods: In this prospective cohort study, HCV genotype 4-infected patients treated with OMV/PTV/r + RBV (n=55) who were registered in a national database
more » ... e included. Study patients were treatment-naïve or interferon plus RBV-experienced with or without compensated cirrhosis. Demographic, clinical and virological data were analyzed. Details of clinical and laboratory adverse events (AEs) were recorded. Results: The mean age of the patients was 55.2, and 52.7% were male. The majority of patients were non-cirrhotic (81.8%), and 69.1% were treatment-naïve. The HCV RNA level was below 800.000 IU/mL in 16 of the cases. Seventy-eight percent of the patients had an underlying disease. SVR12 rate was 98% in all patients. One patient had virological failure. HCV RNA was undetectable at treatment week 4 in 77.6%, at treatment week 8 in 100%, and at end of treatment in 98%. The SVR12 rates were 100% and 88.9% for those without or with compensated cirrhosis (p= 0.176). Rates of AEs and AEsassociated treatment discontinuation were 69.1% and 3.6% in the patients, respectively. Conclusion: The OBV/PTV/r + RBV combination was found to have high efficacy and safety profile in the patients with chronic HCV genotype 4 infection. This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License. Treatment of Chronic HCV Genotype 4 Infection Aygen et al.
doi:10.36519/idcm.2019.19014 fatcat:4f3nlofosffjnfycmd2xurcx7q
Citation

Bilgehan Aygen, Nese Demirturk, Orhan Yıldız, Ilhami Celik, Deniz Kamalak Guzel, Gulden Ersoz, Ayse Batirel, Bahar Ormen, Faruk Karakecili, Pinar Korkmaz, Nazan Tuna, Alper Sener, Riza Aytac Cetinkaya, Emine Turkoglu, Guliz Evik, Nesrin Turker, Umut Devrim Binay, Ercan Yenilmez, Gokmen Zararsız. "Ombitasvir/ Paritaprevir/ Ritonavir + Ribavirin Combination Therapy in Hepatitis C Virus Infected Patients with Genotype 4 in Real-life Practice: A Multicentre Experience." Infectious Diseases and Clinical Microbiology 1.2 (2019) 97-106